The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Unichem Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹5,751 Mil. Unichem Laboratories's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹8,286 Mil.
Hence, Unichem Laboratories's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.69.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Unichem Laboratories Receivables Turnover Related Terms
Unichem Laboratories Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Unichem Laboratories's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:UNICHEMLAB vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories (NSE:UNICHEMLAB) has a Receivables Turnover of 0.69 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Unichem Laboratories and its competitors. According to the industry distribution chart, Unichem Laboratories ranks #802 out of 947 companies in the Drug Manufacturers industry, placing it in the top 84.7%.
Is Unichem Laboratories' Receivables Turnover too high?
Unichem Laboratories' current Receivables Turnover is 0.69. The Drug Manufacturers industry median Receivables Turnover is 5.07. Unichem Laboratories' value of 0.69 is 86.4% below this industry median. Based on the distribution chart, Unichem Laboratories ranks #802 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unichem Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #802 out of 947 companies for Receivables Turnover. This places Unichem Laboratories in the lower half of its industry. The industry median Receivables Turnover is 5.07. Unichem Laboratories' value of 0.69 is 86.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current Receivables Turnover of 0.69 is 86.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Unichem Laboratories and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current Receivables Turnover is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹691.58, compared to a current price of ₹638.75 — trading 7.6% below its estimated fair value. The current Receivables Turnover is 0.69 and 86.4% below the Drug Manufacturers industry median of 5.07. Unichem Laboratories' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current Receivables Turnover is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹638.75 is trading 7.6% below its estimated GF Value™ of ₹691.58.
GuruFocus considers Unichem Laboratories to be Fairly Valued.
Key valuation signals for NSE:UNICHEMLAB:
Receivables Turnover: 0.69
GF Value™: ₹691.58 vs. price of ₹638.75 (7.6% below fair value)
Industry Position: 86.4% below the Drug Manufacturers median (#802 of 947)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
74GF Score
Get the complete analysis for NSE:UNICHEMLAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
